Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785900 · ClinicalTrials.gov registry record · Phase 3
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 3 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT02785900 is a Phase 3 study that was terminated before completion, run by Seagen. The registered enrollment target is 240 participants.
The verdict
NCT02785900, a Phase 3 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.
Interventions
- DRUG placebo
- DRUG azacitidine
- DRUG decitabine
- DRUG 33A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02785900
The ClinicalTrials.gov registry entry for NCT02785900 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT02785900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02785900 about?
NCT02785900 is a clinical study titled "Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia". The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.
What is the current status of trial NCT02785900?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2016-05. Estimated completion is 2017-10-03.
What interventions are being tested in trial NCT02785900?
The interventions under investigation include: placebo (DRUG), azacitidine (DRUG), decitabine (DRUG), 33A (DRUG).
Who is sponsoring clinical trial NCT02785900?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.